The aim of the project is the development of a specific antibody conjugation platform through the application of ZIP-Inteins® technology, which is based on the use of inteins as a conjugation tool.
organisations participate in the project
The project’s innovative strategy will allow access to previously inaccessible areas inside solid tumours.
In order to successfully achieve the project’s aims, a consortium has been formed led by Zera Intein Protein Solutions S.L., in collaboration with Acondicionamiento Tarrasense – LEITAT, and Fundació Institut de Recerca biomédica (Barcelona).
To achieve the objectivesRTC-2015-4336-1 2015-2018
The project has been financed by the Ministry of Science, Innovation and Universities within the RETOS-COLABORACIÓN Subprogram, 2015 Call. Co-financed by the European Union with the aim of promoting technological development, innovation and quality research.
Pharmacogenomic evaluation for the treatment of breast cancer with aromatase inhibitorsRead more
Development of molecular markers to identify long survivors with immunotherapyRead more
Determination of metabolomic profiles in the early diagnosis of breast cancer.Read more
Lung cancer diagnostics based on aptamer technologyRead more